Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Authors
Keywords
-
Journal
Cells
Volume 8, Issue 12, Pages 1522
Publisher
MDPI AG
Online
2019-11-26
DOI
10.3390/cells8121522
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
- (2019) Gilles Salles et al. Clinical Lymphoma Myeloma & Leukemia
- Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
- (2019) Thomas Martin et al. Blood Cancer Journal
- The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
- (2019) Leo Rasche et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
- (2019) Joseph Mikhael et al. BLOOD
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use
- (2019) Jean Kwun et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
- (2019) Djordje Atanackovic et al. LEUKEMIA
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- Global Burden of Multiple Myeloma
- (2018) Andrew J. Cowan et al. JAMA Oncology
- Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).
- (2018) Ajai Chari et al. JOURNAL OF CLINICAL ONCOLOGY
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
- (2018) Hartmut Goldschmidt et al. ANNALS OF HEMATOLOGY
- Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
- (2018) Hanley Abramson INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.
- (2017) J. Endell et al. JOURNAL OF CLINICAL ONCOLOGY
- CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?
- (2016) Francesco Zaja et al. AMERICAN JOURNAL OF HEMATOLOGY
- Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
- (2016) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Multiple myeloma: patient outcomes in real-world practice
- (2016) Kwee Yong et al. BRITISH JOURNAL OF HAEMATOLOGY
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Multiple Myeloma: Diagnosis and Treatment
- (2016) S. Vincent Rajkumar et al. MAYO CLINIC PROCEEDINGS
- HLA-Incompatible Kidney Transplantation — Worth the Risk?
- (2016) Lionel P.E. Rostaing et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
- (2016) Sundar Jagannath et al. Expert Review of Hematology
- Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma
- (2015) Juan Flores-Montero et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Immunosurveillance and therapy of multiple myeloma are CD226 dependent
- (2015) Camille Guillerey et al. JOURNAL OF CLINICAL INVESTIGATION
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
- (2015) B Paiva et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
- (2015) S Yousef et al. Blood Cancer Journal
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
- (2015) Alberto Horenstein et al. Cells
- Flow cytometry CD4+CD26−CD38+ lymphocyte subset in the microenvironment of Hodgkin lymphoma-affected lymph nodes
- (2014) Rosa Di Gaetano et al. ANNALS OF HEMATOLOGY
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
- (2014) I. S. Nijhof et al. CLINICAL CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
- (2012) A Kalff et al. Blood Cancer Journal
- Systematic Review: Kidney Transplantation Compared With Dialysis in Clinically Relevant Outcomes
- (2011) M. Tonelli et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
- (2011) N. Korde et al. BLOOD
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The state of therapy for removal of alloantibody producing plasma cells in transplantation
- (2011) Matthew J. Everly et al. SEMINARS IN IMMUNOLOGY
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
- (2011) M S van der Veer et al. Blood Cancer Journal
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
- (2010) C. Lefaucheur et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Bortezomib: a new player in pre- and post-transplant desensitization?
- (2010) A. Lemy et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search